Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury

P. W. Nance, F. J. Huff, Alberto Martinez-Arizala, Z. Ayyoub, D. Chen, A. Bian, D. Stamler

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study design:Randomized, double-blind, placebo-controlled, two-period crossover.Objectives:To evaluate the efficacy and safety of arbaclofen placarbil (AP) in patients with spasticity secondary to spinal cord injury (SCI).Setting:United States and Canada.Methods:Patients received extended-release AP tablets 10, 20 or 30 mg every 12 h in one of two AP/placebo sequences, with 26 days of each treatment. The primary analysis compared Ashworth scale assessments of muscle tone between AP and placebo for the muscle group with maximum baseline Ashworth score. Secondary endpoints included a patient-rated Severity of Spasticity Scale.Results:In the primary analysis, AP significantly improved Ashworth scores compared with placebo over the dosing interval: least-squares mean reduction versus placebo was 0.60 for AP 20 mg (P=0.0059) and 0.88 for AP 30 mg (P=0.0007). The difference was significant for the pre-morning dose time point, 12 h after the prior evening dose, indicating that efficacy was maintained throughout the dosing interval. Treatment differences for AP 10 mg versus placebo were not significant. Severity of Spasticity ratings were significantly reduced for the combined 20/30-mg group versus placebo (P=0.018). No statistically significant differences between AP and placebo were observed for muscle strength. AP-related AEs were generally mild to moderate in intensity, and none led to early withdrawal or were serious.Conclusion:AP was well tolerated at all investigated dosages and, when administered at doses of 20 or 30 mg twice daily, was efficacious in reducing spasticity due to SCI.

Original languageEnglish
Pages (from-to)974-980
Number of pages7
JournalSpinal Cord
Volume49
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Spinal Cord Injuries
Safety
Placebos
arbaclofen placarbil
Muscles
Muscle Strength
Least-Squares Analysis
Tablets
Canada

Keywords

  • arbaclofen placarbil
  • baclofen
  • efficacy
  • safety
  • spasticity
  • spinal cord injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. / Nance, P. W.; Huff, F. J.; Martinez-Arizala, Alberto; Ayyoub, Z.; Chen, D.; Bian, A.; Stamler, D.

In: Spinal Cord, Vol. 49, No. 9, 01.09.2011, p. 974-980.

Research output: Contribution to journalArticle

Nance, P. W. ; Huff, F. J. ; Martinez-Arizala, Alberto ; Ayyoub, Z. ; Chen, D. ; Bian, A. ; Stamler, D. / Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. In: Spinal Cord. 2011 ; Vol. 49, No. 9. pp. 974-980.
@article{dbf62f0aed0444ddb9d67ea6f68a5237,
title = "Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury",
abstract = "Study design:Randomized, double-blind, placebo-controlled, two-period crossover.Objectives:To evaluate the efficacy and safety of arbaclofen placarbil (AP) in patients with spasticity secondary to spinal cord injury (SCI).Setting:United States and Canada.Methods:Patients received extended-release AP tablets 10, 20 or 30 mg every 12 h in one of two AP/placebo sequences, with 26 days of each treatment. The primary analysis compared Ashworth scale assessments of muscle tone between AP and placebo for the muscle group with maximum baseline Ashworth score. Secondary endpoints included a patient-rated Severity of Spasticity Scale.Results:In the primary analysis, AP significantly improved Ashworth scores compared with placebo over the dosing interval: least-squares mean reduction versus placebo was 0.60 for AP 20 mg (P=0.0059) and 0.88 for AP 30 mg (P=0.0007). The difference was significant for the pre-morning dose time point, 12 h after the prior evening dose, indicating that efficacy was maintained throughout the dosing interval. Treatment differences for AP 10 mg versus placebo were not significant. Severity of Spasticity ratings were significantly reduced for the combined 20/30-mg group versus placebo (P=0.018). No statistically significant differences between AP and placebo were observed for muscle strength. AP-related AEs were generally mild to moderate in intensity, and none led to early withdrawal or were serious.Conclusion:AP was well tolerated at all investigated dosages and, when administered at doses of 20 or 30 mg twice daily, was efficacious in reducing spasticity due to SCI.",
keywords = "arbaclofen placarbil, baclofen, efficacy, safety, spasticity, spinal cord injury",
author = "Nance, {P. W.} and Huff, {F. J.} and Alberto Martinez-Arizala and Z. Ayyoub and D. Chen and A. Bian and D. Stamler",
year = "2011",
month = "9",
day = "1",
doi = "10.1038/sc.2011.43",
language = "English",
volume = "49",
pages = "974--980",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury

AU - Nance, P. W.

AU - Huff, F. J.

AU - Martinez-Arizala, Alberto

AU - Ayyoub, Z.

AU - Chen, D.

AU - Bian, A.

AU - Stamler, D.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Study design:Randomized, double-blind, placebo-controlled, two-period crossover.Objectives:To evaluate the efficacy and safety of arbaclofen placarbil (AP) in patients with spasticity secondary to spinal cord injury (SCI).Setting:United States and Canada.Methods:Patients received extended-release AP tablets 10, 20 or 30 mg every 12 h in one of two AP/placebo sequences, with 26 days of each treatment. The primary analysis compared Ashworth scale assessments of muscle tone between AP and placebo for the muscle group with maximum baseline Ashworth score. Secondary endpoints included a patient-rated Severity of Spasticity Scale.Results:In the primary analysis, AP significantly improved Ashworth scores compared with placebo over the dosing interval: least-squares mean reduction versus placebo was 0.60 for AP 20 mg (P=0.0059) and 0.88 for AP 30 mg (P=0.0007). The difference was significant for the pre-morning dose time point, 12 h after the prior evening dose, indicating that efficacy was maintained throughout the dosing interval. Treatment differences for AP 10 mg versus placebo were not significant. Severity of Spasticity ratings were significantly reduced for the combined 20/30-mg group versus placebo (P=0.018). No statistically significant differences between AP and placebo were observed for muscle strength. AP-related AEs were generally mild to moderate in intensity, and none led to early withdrawal or were serious.Conclusion:AP was well tolerated at all investigated dosages and, when administered at doses of 20 or 30 mg twice daily, was efficacious in reducing spasticity due to SCI.

AB - Study design:Randomized, double-blind, placebo-controlled, two-period crossover.Objectives:To evaluate the efficacy and safety of arbaclofen placarbil (AP) in patients with spasticity secondary to spinal cord injury (SCI).Setting:United States and Canada.Methods:Patients received extended-release AP tablets 10, 20 or 30 mg every 12 h in one of two AP/placebo sequences, with 26 days of each treatment. The primary analysis compared Ashworth scale assessments of muscle tone between AP and placebo for the muscle group with maximum baseline Ashworth score. Secondary endpoints included a patient-rated Severity of Spasticity Scale.Results:In the primary analysis, AP significantly improved Ashworth scores compared with placebo over the dosing interval: least-squares mean reduction versus placebo was 0.60 for AP 20 mg (P=0.0059) and 0.88 for AP 30 mg (P=0.0007). The difference was significant for the pre-morning dose time point, 12 h after the prior evening dose, indicating that efficacy was maintained throughout the dosing interval. Treatment differences for AP 10 mg versus placebo were not significant. Severity of Spasticity ratings were significantly reduced for the combined 20/30-mg group versus placebo (P=0.018). No statistically significant differences between AP and placebo were observed for muscle strength. AP-related AEs were generally mild to moderate in intensity, and none led to early withdrawal or were serious.Conclusion:AP was well tolerated at all investigated dosages and, when administered at doses of 20 or 30 mg twice daily, was efficacious in reducing spasticity due to SCI.

KW - arbaclofen placarbil

KW - baclofen

KW - efficacy

KW - safety

KW - spasticity

KW - spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=80052424754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052424754&partnerID=8YFLogxK

U2 - 10.1038/sc.2011.43

DO - 10.1038/sc.2011.43

M3 - Article

C2 - 21577221

AN - SCOPUS:80052424754

VL - 49

SP - 974

EP - 980

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 9

ER -